Abstract: The present invention relates to separation matrices comprising base matrices with first ligands comprising hydrophobic functions covalently bound to said base matrices and with extenders covalently bound to said base matrices, said extenders comprising second ion exchange ligands.

Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.

Abstract: Chemically reactive dyes that are intramolecularly crosslinked with a water-soluble bridge, their bioconjugates and their uses are described. Reactive fluorescent dyes that have a water-soluble bridge are superior to those of conjugates of spectrally non-crosslinked dyes or the dyes that are crosslinked with a hydrophobic bridge. The invention includes reactive fluorescent dyes, their biological conjugates and uses.

Abstract: Novel aldehyde-functionalized polysaccharide compositions containing pendant dialdehyde groups are described that are more stable in aqueous solution than oxidized polysaccharides. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.

Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

Abstract: A method of manufacturing porous polymer particles with improved filterability is described. One or more first water phases are formed comprising an anionic hydrocolloid with a mass-per-charge value of less than 600 and a relatively minor amount, compared to the anionic hydrocolloid, of at least one of a nonionic, cationic, zwitterionic, or weakly anionic water soluble or dispersible polymer, where the weakly anionic water soluble or dispersible polymer has a mass-per-charge value of larger than 600. A water-in-oil emulsion is formed by dispersing the one or more first water phases into an organic phase comprising at least one of either (i) preformed polymer dissolved in an organic solvent or (ii) polymerizable monomers, and homogenizing. A water-in-oil-in-water multiple emulsion is formed by dispersing the water-in-oil emulsion into a second water phase containing a stabilizing agent and homogenizing.

Abstract: The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide. In a particular embodiment, the foregoing composition further includes at least one cell-targeting agent. The invention is also directed to methods that utilize these compositions for removing or reducing cholesterol and other lipids in a mammal suffering from an elevated level of cholesterol and/or other lipid.

Abstract: The present disclosure relates to amphiphilic compounds, self assembling compositions formed from the amphiphilic compounds and methods of making such compositions.

Abstract: The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.

Abstract: The present disclosure relates to compounds and medical devices activated with a solvophobic material functionalized with a first reactive member and methods of making such compounds and devices.

Abstract: The present invention is related to a modified hydroxypolymer conjugates preferably a guanidine-dextran conjugate having a tumor cell killing activity. The modified hydroxypolymer conjugate is used as medicine, particularly for manufacturing a medicine or tumor killing composition for treating tumors. A method for producing said hydroxypolymer conjugate and a method for killing cancer cells and treating tumors is also disclosed. The invention is also related to a method for killing tumor cells and treating tumors by administering an effective amount of the modified hydroxypolymer conjugate.

Abstract: Novel aldehyde-functionalized polysaccharide compositions are described that are more stable in aqueous solution than oxidized polysaccharides or other types of polysaccharides containing pendant aldehyde groups. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.

Abstract: Dextran for preparing medicine for anti-lung cancer, has repeated structure unit and molecular weight of 1.5-2.5 million Daltons. The dextran is extracted from land slug.

Abstract: The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate).

Abstract: Compositions and methods of making a modified polyhydroxylated polymer comprising a polyhydroxylated polymer having reversibly modified hydroxyl groups, whereby the hydroxyl groups are modified by an acid-catalyzed reaction between a polydroxylated polymer and a reagent such as acetals, aldehydes, vinyl ethers and ketones such that the modified polyhydroxylated polymers become insoluble in water but freely soluble in common organic solvents allowing for the facile preparation of acid-sensitive materials. Materials made from these polymers can be made to degrade in a pH-dependent manner. Both hydrophobic and hydrophilic cargoes were successfully loaded into particles made from the present polymers using single and double emulsion techniques, respectively. Due to its ease of preparation, processability, pH-sensitivity, and biocompatibility, of the present modified polyhydroxylated polymers should find use in numerous drug delivery applications.

Abstract: An affinity matrix comprising a metal ion covalently attached thereto and methods for making and using the same are described. The matrix has affinity for various phosphorylated biomolecules, such as phosphoproteins/phosphopeptides. The matrix may be used in a variety of different applications, including phospho-biomolecule (e.g., phosphoprotein and phosphopeptides) enrichment/purification and characterization applications. Also provided are kits and systems that include the matrix.

Abstract: The present invention provides methods for making porous crosslinked polysaccharide hydrogel coated structures. The methods include impregnating a porous substrate with a room temperature stable aqueous polysaccharide solution containing, water, a polysaccharide having a concentration in the aqueous solution from about 0.1% to about 20%, a gel-inhibiting agent having a concentration in the aqueous solution from about 18 to about 54%, and an anionic fluorosurfactant having a concentration in the aqueous solution from about 0.001% to about 10% by total weight of the aqueous solution. Followed by evaporating the water from the polysaccharide coating; and exposing the dehydrated polysaccharide coating to a gelling agent form a porous polysaccharide hydrogel coated substrate. The hydrogel coated substrate is exposed to a crosslinking agent to form a porous crosslinked polysaccharide hydrogel coated substrate.

Abstract: The invention relates to a hot melt adhesive, comprising at least one polysaccharide ester gained by a reaction of a polysaccharide with an imidazolide in melted imidazole. The invention relates, further, to a process for producing the hot melt adhesive, in which imidazole is melted, and an acid chloride and/or an acid anhydride and/or a lactone is reacted in and with the melted imidazole to form an imidazolide, whereby at least one polysaccharide is added to the melted imidazole, whereby the polysaccharide is reacted with the imidazolide to form a polysaccharide ester.

Abstract: A novel anionic polysaccharides functionalized by at least one hydrophobic acid derivative. These novel anionic polysaccharides including hydrophobic groups have good biocompatibility and their hydrophobicity can be easily adjusted without detrimentally affecting the biocompatibility or the stability. A method of synthesis which makes it possible to produce them and to pharmaceutical compositions including them.

Abstract: Provided herein are water-soluble carbohydrate polymers which are monoderivatized at their reducing terminus, such that the carbohydrate polymers can be selectively conjugated at a single location. Also provided are methods of preparation and conjugation of the monoderivatized carbohydrate polymers.

Abstract: The present invention discloses a new type of water-soluble polydextrose. This new type of polydextrose contains at least 75% by weight of saccharide molecules having a degree of polymerisation (DP) of 5 or more and characterised in that the non-digestible fiber content is at least 80% by weight. Further, the present invention relates to a process for preparing this new type of polydextrose and to the use of this polydextrose in products such as food products, pharmaceutical products and personal care products.

Abstract: The invention relates to a modified separating material having improved properties, to the preparation thereof, and to the use thereof for the separation of charged biopolymers from liquids.

Abstract: Manufactured hyaluronic acid products are used in numerous surgical applications including viscoelastic supplementation for the treatment of osteoarthritis, however, traditional sterilization techniques result in the breakdown of such high molecular weight viscoelastic biopolymers and are thus unsuitable. Disclosed are processes for obtaining concentrated sterile solutions of high molecular weight biopolymers such as hyaluronic acid. The processes include filter sterilization with a dilute preparation of the biopolymer, and concentration of the dilute filter sterilized biopolymer by ultrafiltration to a desired concentration.

Abstract: Polysaccharide including carboxyl functional groups. The polysaccharide being chosen from the group of anionic synthetic polysaccharides including 1,6 bonds obtained from neutral polysaccharides of which at least one of a carboxyl functional groups is esterified by a hydrophobic alcohol (-Ah) (residue of a hydrophobic alcohol). The hydrophobic alcohol (Ah) being grafted or bonded to the anionic polysaccharide by a function F (ester function), which results from coupling between the carboxylate function of the anionic polysaccharide and hydroxyl function of the hydrophobic alcohol. Carboxyl functions of anionic polysaccharide, which are not substituted, are in the form of carboxylate of a cation. The polysaccharide including carboxyl functional groups are amphiphilic at neutral pH. It also relates to its use for the preparation of pharmaceutical compositions and the pharmaceutical compositions comprising a polysaccharide and at least one active principle.

Abstract: A method of lowering blood glucose in a mammal includes administering orally or by injection or inhalation a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin or other therapeutic agents.

Abstract: Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and an oligoaspartate bone targeting agent, and processes of preparing same, are further disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment and monitoring of bone related disorders are also disclosed.

Abstract: The invention disclosed here has several key elements: direct probe-on-sensor detection, mesh probe, and mesh reporter. Furthermore, the mesh probe and reporter shall have some physical cross-linking between the polymer backbone(s), either covalently or non-covalently. In combination, this invention enables one to build an ultra-sensitive, low-cost, and highly portable system for molecular detection. Among its many potential applications is a direct detection of nucleic acids in crude lysate in a multiplex format, without the requirements for nucleic acids extraction and amplification. Such an improvement is likely to change the practice of genotyping and gene expression profiling done in a clinic setting. Another application is an ultrasensitive ELIZA assay in a multiplex format.

Abstract: Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration of the compounds of the invention orally, topically, subcutaneously, by muscular injection, by intraperitoneal injection and by intravenous injection.

Abstract: Fluid compositions and methods for lubrication of mammalian joints are disclosed, including both natural and artificial fluids. Synovial fluid acts to lubricate the bearing surfaces of bones and bone-like structures which are held in frictional contact within biological joints. Such fluids may be used to treat arthritic, injured, and diseased joints. Synovial fluid containing a dextran-based hydrogel with lipids provides enhanced rheological and tribological properties of such a fluid. Phospholipids are particularly useful in dextran-based compositions for synovial fluid. One phospholipid that can be used advantageously in synovial fluid is dipalmitoyl phosphatidylcholine (DPPC).

Abstract: The present invention is relates to method for production of a biomolecule adsorbent with a pentadentate ligand with very strong chelating properties, and to methods for use thereof for, for example, protein purification, detection or binding. The biomolecule adsorbent comprises the formula: wherein Q is a carrier, S is a spacer, L is an amide linkage, X is COOH, and n=2 or 3.

Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.

Abstract: An object of the present invention is to provide a biosensor and a method for immobilizing a physiologically active substance, by which preconcentration effects can be obtained at a pH that is equivalent to or higher than the isoelectric point of the physiologically active substance and the physiologically active substance can be covalently bound to the surface. The present invention provides a biosensor comprising a solid substrate to which a polymer having a primary or secondary amino group is bound, by which a physiologically active substance can be chemically immobilized following preconcentration of the substance at a pH that is equivalent to or higher than the isoelectric point of the substance.

Abstract: Methods and materials are disclosed relating to an improved method for amplifying a signal in a diagnostic assay for an analyte, using an amplification polymer that multivalently binds to one or more non-analyte-specific binding site of the multivalent bridge conjugate, if present on the solid support.

Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.

Abstract: The invention relates to a biocompatible metastable intermediate material for controlling the mobility of at least one biologically active substance. An example of the invention is a hydrogel formed by cross-linked sodium hyaluronate treated with an oxidizing agent so as to open sugar rings and form aldehyde groups. The gel according to the invention is sterilized, e.g. by autoclaving.

Abstract: The invention relates to methods for the quantitative and qualitative detection of an analyte in an assay as well as appropriate reagents therefor, especially a carrier molecule to which one or several analyte-specific binding partners are bound and which is provided with additional binding points for a specific binding partner X or Y that is associated with a component of a signal-forming system. Also disclosed is the use of such a conjugate particularly in homogeneous binding tests.

Abstract: The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.

Abstract: The present invention provides viscoelastic gel compositions comprising microparticles which are capable of interacting with each other in a non-ionic manner, thus forming a gel network. The gel compositions may incorporate active agents and provide controlled release of such agents. The compositions are useful as injectable depot formulations of therapeutic compounds. In a further aspect, microparticles capable of gel formation in an aqueous environment are provided, as well as method of making viscoelastic gels based on the interaction of uncharged microparticles. Moreover, the invention discloses kits for making viscoelastic gel compositions and uses thereof.

Abstract: The invention relates to solid organometallic hybrids with modified surface. Said solid may be used for example for the encapsulation and vectoring of molecules of interest such as active pharmaceutical agents, compounds of interest in cosmetics and markers, for example, contrast agents. Said solids show good results in terms of loading capacity in medicament agents and in biocompatibility.

Abstract: The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprise the steps consisting of a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide and one cross-linking agent b) freezing the aqueous solution of step a) c) sublimating the frozen solution of step b). characterized in that step b) is performed before the cross-linking of the polysaccharide occurs in the solution of step a).

Abstract: To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.

Abstract: Disclosed is a method for indirectly coupling a small molecule ligand to a molecule to be labelled with the ligand, the method comprising the step of: contacting a scaffold molecule, to which is attached at least one small molecule ligand, with the molecule to be labelled, the scaffold molecule having at least one group which is reactive towards a receiver moiety present or formed in situ on the molecule to be labelled, so as to forma bond between the scaffold molecule and the molecule to be labelled, thereby indirectly coupling the small molecule ligand to the molecule to be labelled.

Abstract: A process for the selective binding of an aggregating abnormal form of a protein in the presence of the nonaggregating normal form of the protein, including contacting under selective binding conditions a material containing both the abnormal and normal forms with a binding agent which is a polyionic material having a binding avidity for the aggregating form of the protein as present in the sample.

Abstract: The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of heavy metal ions in a sample.

Abstract: The present invention discloses modified polymer conjugates of a polymer and a drug having reduced toxicity relative to the unmodified parent compound while retaining substantially the same degree of therapeutic activity as of the unmodified parent compound.

Abstract: Provided are an organic-inorganic hybrid scaffold with surface-immobilized nano-hydroxyapatite, and a method for the fabrication thereof. The scaffold is fabricated by reacting an acid group present on a surface of nano-hydroxyapatite with a primary amine present on a surface of a polymer support in the presence of EDC (1-ethyl-3-dimethylaminopropyl carbodiimide) to immobilize nano-hydroxyapatite onto the surface of the polymer support. The surface of nano-hydroxyapatite is previously grafted with poly(ethylene glycol methacrylate phosphate) (PolyEGMP) having phosphonic acid functionality or with a polymer having carboxylic acid functionality.

Abstract: Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed.

Abstract: Provided herein are methods, devices, and compositions for dermal filling. Also described herein are dermal filler cross-linked compositions and methods for making such compositions. Such compositions comprise, for example, a cross-linked composition of hyaluronic acid, derivatives of hyaluronic acid or mixtures thereof, alginic acid, derivatives of hyaluronic acid or mixtures thereof and calcium ions.

Abstract: The present invention relates to a method of preparing a separation matrix comprising at least one insoluble carrier to which sulphate ligands have been attached via extenders, which method comprises coupling, in a first step, of the sulphate ligands to the extenders and, in a subsequent step, attaching the extenders to an insoluble carrier. The invention also relates to a separation matrix comprised of at least one insoluble carrier to which sulphate ligands have been attached via extenders. Advantageously, no sulphate ligands are directly attached to the insoluble carrier. The extenders may be natural polymers, such as dextran, and the insoluble carrier may be made from natural polymers, such as agarose, or synthetic polymers. The invention also relates to a method of purifying virus, such as influenza virus, using a separation matrix according to the invention.

Abstract: The present invention describes polymers containing 1,2-dithiolanes capable of acting as scavengers of free radicals, metals and reactive oxygen species. Also described are methods of synthesizing the antioxidant 1,2-dithiolane derivatives and polymerization thereof to produce biodegradable antioxidant polymers. The antioxidant polymers of the present invention may be used to treat diseases or conditions caused by oxidative stress and other free radical mediated conditions. The antioxidant polymers may also be used for the preparation of antioxidant particulate delivery devices of therapeutic agents.